A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
about
Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF ReceptorTumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2.A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.Nanocell targeting using engineered bispecific antibodies.Advances in targeted therapeutic agents.Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.Ligand binding induces a conformational change in epidermal growth factor receptor dimers.A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation.Epidermal growth factor receptor-targeted lipid nanoparticles retain self-assembled nanostructures and provide high specificity.An EGFR targeting nanoparticle self assembled from a thermoresponsive polymer
P2860
Q27664092-2664B2F4-1AA3-4021-8A87-A784C2305125Q34069375-860BBCD1-C0AE-4710-B023-337EAAE1B089Q34236834-5C30211D-690A-4A89-8353-D2A2E003ED8BQ34625617-B07CA053-C6A4-4B14-807E-04250FA2AC02Q34634742-CA73D6D4-CB6F-44F1-93AD-6829FA74F7F7Q35791377-D5B8C3D4-EFFE-4EDD-A3A0-5018B137DAD4Q36174467-5D97B92C-7D58-4F75-B275-54F62239C552Q36211456-12C3A0CC-0C11-4937-9B7B-A3A8B68073D5Q38029122-76237E75-5D59-4EE1-8D73-F74AF4D54799Q39002694-59F2301D-00DB-4D67-93EC-769245BDA6B8Q39242623-3B3B006C-CDB7-42FC-90E8-13A0D121F065Q39303587-4523B551-113A-4184-8650-5F77ABD723ACQ41606644-AAF24832-3479-49BD-B3A6-C2234FEA8620Q57252648-361CB405-917A-4E26-8AA2-CAE14DEEDA93
P2860
A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@en
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@nl
type
label
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@en
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@nl
prefLabel
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@en
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@nl
P2093
P2860
P50
P1476
A truncated soluble epidermal ...... anti-tumour activity in vivo.
@en
P2093
Andrew D Nash
Antony W Burgess
Colin W Ward
Edouard C Nice
George Lovrecz
John D Bentley
Julie Rothacker
Peter H Hoyne
P2860
P304
P356
10.1080/08977190902843565
P577
2009-06-01T00:00:00Z